NUTRITION IN CONTEXTNovember 16, 2026
Heart Nutrition
Brief
Heart Health / EVIDENCE GUIDE

Niacin Can Raise HDL Without Preventing More Cardiovascular Events on Statin Therapy

A guide to AIM-HIGH and HPS2-THRIVE, showing why better lipid numbers did not translate into better outcomes and why side effects matter.

Flush der Hand und Unterarm ca. 30 min nach Einnahme von 200 mg Niacin auf nüchternen Magen
Flush Niacin Hand · JBCH · CC BY-SA 4.0 · Source · License
THE KEY TAKEAWAY

In large modern trials, adding high-dose niacin to effective statin therapy improved some lipid numbers but did not reduce cardiovascular events and increased harms.

A better biomarker is not automatically a better outcome

Niacin can lower LDL cholesterol and triglycerides while raising HDL cholesterol. Those changes made it an attractive add-on when low HDL was treated as a target. But a risk marker is not necessarily a successful treatment target. The decisive question is whether changing the marker with a specific intervention reduces heart attacks, strokes, or deaths without unacceptable harm.

Nutritional niacin requirements and prescription-level lipid treatment are separate topics. The doses tested for dyslipidemia are far above ordinary dietary needs and can cause flushing, liver problems, glucose changes, and other adverse effects. A vitamin label can obscure the fact that high-dose niacin behaves like a drug and requires medical supervision.

Roasted baby mussels on penne, with peanuts, garlic olive oil, and black pepper - Massachusetts, USA.
Roasted baby mussels on penne, with peanuts, garlic olive oil, and black pepper - Massachusetts · Daderot · CC0 · Source · License

AIM-HIGH tested niacin on top of statins

AIM-HIGH enrolled people with established atherosclerotic cardiovascular disease, low HDL, and elevated triglycerides whose LDL was well controlled with statin-based therapy. Extended-release niacin improved HDL and triglyceride levels, but the trial stopped early for lack of efficacy after a mean three years. It did not provide incremental clinical benefit for the primary cardiovascular endpoint.

The result directly challenges the claim that raising HDL with niacin necessarily reduces events. It does not mean HDL has no relationship with risk. It means that this method of changing HDL, in this treated population, did not improve outcomes. Observational associations and treatment effects are different forms of evidence and should not be blended together.

HPS2-THRIVE confirmed the outcome problem

HPS2-THRIVE randomized 25,673 adults with vascular disease to extended-release niacin plus laropiprant or placebo while they received statin-based LDL-lowering therapy. The active regimen did not significantly reduce major vascular events. It did increase serious adverse events involving diabetes control, gastrointestinal and musculoskeletal systems, skin, infection, and bleeding.

Laropiprant was included to reduce flushing, so the formulation was not identical to every niacin product. Still, the trial provides strong evidence against assuming that favorable lipid changes guarantee net clinical benefit. A supplement seller should not cite the laboratory effect while omitting the event outcome and adverse-event profile from a large randomized trial.

Flush-free does not mean equivalent or proven

Products marketed as flush-free may contain inositol hexanicotinate or other forms that do not deliver the same pharmacologic exposure as nicotinic acid. Avoiding flushing does not prove cholesterol benefit, and a different form cannot borrow outcome evidence from prescription niacin. Read the ingredient identity rather than treating every product with the word niacin as interchangeable.

Immediate-release, sustained-release, and extended-release preparations can differ in absorption and adverse effects. Liver toxicity is a particular concern with some sustained-release products. Anyone considering high-dose niacin needs clinician-directed dosing, laboratory monitoring, and a review of diabetes, gout, liver disease, alcohol use, and interacting medicines.

Tuna steak w/baked potato
Tuna steak w baked potato (3397219643) · Karen and Brad Emerson · CC BY 2.0 · Source · License

Use outcomes to guide the conversation

A useful discussion begins with overall cardiovascular risk, the reason lipid treatment was prescribed, current LDL control, side effects, and therapies proven to reduce events. It should not start with a goal of forcing HDL above a particular number. Modern prevention decisions use multiple risk factors and outcome evidence rather than one attractive laboratory change.

Do not add over-the-counter niacin to a statin regimen or substitute it for prescribed therapy without medical guidance. The AIM-HIGH and HPS2-THRIVE lessons are unusually clear: treatment can move biomarkers in the expected direction while failing to help patients overall. Heart-health reporting should lead with that outcome, not with the biochemical result that is easiest to market.

Label language can blur dose and purpose

A supplement facts panel may list niacin in milligrams and as a percentage of Daily Value, but that presentation does not show whether the amount is intended for basic nutrition or pharmacologic lipid effects. Compare the chemical form and total daily exposure across all products.

Claims such as energy support may refer to niacin’s normal nutrient role, not evidence that the product treats fatigue or cardiovascular risk. A large Daily Value percentage is not proof of added benefit. At high doses, the conversation belongs with a clinician, not a front-label percentage. Monitoring can include liver enzymes, glucose, uric acid, symptoms, and the reason the product is being considered in the first place.

Sources & further reading

  1. Niacin in Patients With Low HDL Cholesterol Receiving Intensive Statin Therapy (AIM-HIGH) ↗
  2. Effects of Extended-Release Niacin With Laropiprant in High-Risk Patients (HPS2-THRIVE) ↗
  3. Serious Adverse Effects of Extended-Release Niacin/Laropiprant ↗

This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.

More on Heart Health →